UNSPSC 51271921: Procaine borate

This classification denotes an anesthetic agent with the molecular formula C13H20N2O2.5BHO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B42E10825B, chemically known as 2-(diethylamino)ethyl p-aminobenzoate borate (1:5), but more generally known as procaine borate, which bears US NIH Compound Identifier 67418. European Medicines Agency schedules procaine borate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10056MIG.

Most nations, for tariff purposes, schedule procaine borate under HS 29224995. Procaine borate bears US NLM identifiers UMLS ID C3273344 and NCI Concept Code C97301. SMILES: B(=O)O.B(=O)O.B(=O)O.B(=O)O.B(=O)O.CCN(CC)CCOC(=O)C1CCC(CC1)N.

UNSPSC 51271921 Procaine borate is a Commodity code for pharmaceutical active ingredients and excipients supplied through state and local cooperative purchasing vehicles. State and local procurement under this code centers on securing generic pharmaceutical products and over-the-counter medications through established distribution wholesalers, with vendors required to maintain current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, and contractual relationships with authorized drug wholesalers that support chargeback systems. Issuing bodies include state departments of administration and multistate cooperative purchasing alliances; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent buyer and structures awards to reach state and local government facilities across participating jurisdictions.

MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products, closing March 26, 2026, exemplifies the code's current activity. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and specifies detailed product identification including National Drug Codes, SKUs, UPCs, generic descriptions, strength, dosage form, and trade names. Evaluation weighting emphasizes price competitiveness (75 percent) and fixed pricing for the contract term (10 percent), with secondary criteria covering EDI capability, administrative fee format compliance, and pricing flexibility options including flat price, net price formats (NF30, NF60, NF90), and WAC-minus structures. Contract awards are effective July 1, 2026, for a two-year term with optional extensions, and vendors must maintain insurance coverage including $5,000,000 commercial general liability, $2,000,000 network security and privacy liability, and $2,000,000 professional liability. Minnesota and Oregon represent the documented geographic scope, with the procurement open to manufacturers able to deliver products by May 15, 2026.